Moderna Inc (MRNA) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.51, significantly surpassing Wall Street's consensus estimate of $-2.15 by $1.64. Additionally, revenue reached $1.0 billion, exceeding expectations of $0.9 billion.
This update provides insight into Moderna's operational performance and financial health. The firm, headquartered in Cambridge, Massachusetts, specializes in developing transformative medicines based on messenger ribonucleic acid (mRNA). With a diverse pipeline of 44 therapeutic and vaccine programs, including late-stage developments for its COVID-19 vaccine Spikevax and its respiratory syncytial virus vaccine, Moderna continues to advance its innovative approach to medicine.
The company will host its earnings conference call at BMO to discuss these results and provide further commentary on its business performance. Investors may find value in reviewing the full earnings release and management's insights for a comprehensive understanding of the quarter's outcomes and future outlook.
As of November 7, 2025, Moderna's market capitalization stands at $9.43 billion, with a trailing twelve-month EPS of -7.5. Looking ahead, the company is scheduled to report earnings again on April 28, 2026, with an EPS estimate of $-2.4616 and revenue expectations of $0.2 billion.